Fingerprint
Dive into the research topics of 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically